Application of William True Davis, Jr., and Fred M. Murdock

305 F.2d 501, 49 C.C.P.A. 1196
CourtCourt of Customs and Patent Appeals
DecidedJuly 18, 1962
DocketPatent Appeal 6825
StatusPublished
Cited by4 cases

This text of 305 F.2d 501 (Application of William True Davis, Jr., and Fred M. Murdock) is published on Counsel Stack Legal Research, covering Court of Customs and Patent Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Application of William True Davis, Jr., and Fred M. Murdock, 305 F.2d 501, 49 C.C.P.A. 1196 (ccpa 1962).

Opinion

WORLEY, Chief Judge.

This is an appeal from the decision of the Board of Appeals affirming the Primary Examiner’s rejection of all claims in appellants’ patent application 1 entitled “Vaccine.”

The references relied on are:

Wilson, “Biological Products,” September 1912, pages 274-275.
New and Non Official Remedies, 1953, pages 419-275.
Freund, Annual Review of Microbiology, 1947, Vol. I, page 296.
Ward et al., Proc. Soc. Exptl. Biol, and Med., July 1950, pages 536-537.
Ramon et al., Squibb Abst. Bulletin, Nov. 1, 1950, Vol. 23, page 1382.

Appellants’ invention relates to a single injectable dose of two antigens for immunizing animals against two diseases, viz., immunizing hogs against hog cholera and swine erysipelas or immunizing dogs against canine distemper and canine hepatitis.

Although the antigens may be of either viral or bacterial origin, the application states that one antigen must be live and the other dead.

Regarding prior practice in this field, appellants’ specification states:

“As will be readily appreciated, wherever it is necessary to effect immunization against two or more diseases, it is most desirable to be able to accomplish this by a single injection. To this end various antigens have previously been combined to form single vaccines capable of simultaneous immunization against several diseases. However, the combination of a live antigen and a dead one has never before been accomplished. This is apparently due to the fact that chemi’cal attenuating and preserving agents, *502 which are usually present in dead vaccines, produce, or at least were thought to produce, a harmful effect on the live antigens.
“As a result, wherever animals are to be immunized against several diseases requiring the use of both live and dead antigens, it has been the practice to effect immunization separately against each disease. For example, swine are normally immunized against swine erysipelas and hog cholera, this being accomplished by two separate immunizations using respectively a killed bacterin for the swine erysipelas and a modified live vaccine for the hog cholera.”

The specification further states that it is necessary to freeze-dry the live hog cholera vaccine “in order to stabilize and preserve potency” and, at the time of use to dilute the dessicated vaccine with sterile water “or other conventional diluents such as phenol glycerin” to obtain the proper dose. Appellants’ invention eliminates the use of such diluents by combining a “dried” live vaccine with a dead fluid antigen. The specification states:

“ * * * Thus, when hog cholera vaccine and swine erysipelas bacterin are injected separately, in conventional manner, it is customary to use a total of at least 7 cc. of the two antigens (usually 2 cc. hog cholera vaccine and 5 cc. of the erysipelas bacterin). On the other hand, when using the combination of the present invention, the volume of a satisfactory dose is reduced to about 5 cc. representing a saving of about 30%.”

Claims 10 and 11 are representative of the claims on appeal and read:

“10. A single injectable dose of antigens for treating an animal from the group consisting of canines and hogs, said antigen being selected from the group consisting of bacterial and viral antigens effective against different animal infections, at least one of said antigens being live and another dead, said dose-being in the form of a suspension of' the antigens and the antigens being-each present in sufficient concentration to produce immunity against said infections and thereby protect the animal, said dose of antigens being selected from the group consisting of (1) a mixture of swine-erysipelas bacterin and a hog cholera vaccine and (2) a mixture of a canine distemper vaccine and a. canine hepatitis vaccine.
“11. The method of preparing a single injectable dose of antigens for treating an animal from the group consisting of canines and hogs, said antigen being selected from the group consisting o-f bacterial and viral antigens effective against different animal infections, at least one-of said antigens being live and another dead, comprising the steps of' reconstituting at least one of said desiccated antigens with a liquid, containing another of said antigens- and forming a liquid suspension of said antigens, the antigens in said' suspension being each present in-, sufficient concentration to produce immunity against said infections- and thereby protect the animal, said dose of antigens being selected from the group consisting of (1) a mixture of swine erysipelas bacterin and a hog cholera vaccine and (2) a mixture of a canine distemper vaccine and a canine hepatitis vaccine.”

The four remaining claims are drawn to the “single injectable dose of antigens” and are more limited than claim 10, claim 11 being the only method claim.

The board set forth the examiner’s position as follows:

“The examiner has rejected the claims as unpatentable over Wilson, who shows a polyvalent vaccine or New and Non Official Remedies showing a mixture of vaccines with and without aluminum hydroxide. In view of the admitted conventional’ *503 administration of either live or dead hog cholera virus and erysipelas bacterins to immunize against both these prevalent diseases, the examiner considers it without invention to use the old expedient of mixing vaccines for simultaneous administration.”

'The examiner further relied on Freund, Ward, and Ramon as showing the compatability of live and dead antigens as well as enhancement of the immunity produced by one of the antigens.

The board found the examiner’s position to be “without reversible error” and further held that “the facts herein are indistinguishable from those in the case of Funk Brothers Seed Company v. Kalo Inoculant Company, 1948 C.D. 671; 608 O.G. 641; 333 U.S. 127 [68 S.Ct. 440, 92 L.Ed. 588] ; 76 USPQ 280.” It then concluded:

“Accordingly, even though the claimed combination is new, useful, and provides an advantage in that a .single administration injection is necessary, to be patentable it also must satisfy the statutory requirements of invention or discovery. Funk Brothers Seed Company v. Kalo Inoculant Company, supra.”

The issue presented is whether “the •differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.” 35 U.S. C. § 103.

What was the state of the prior art at that time?

Wilson, a 1912 publication, states regarding dead bacterial vaccines:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Stauffer
290 F. App'x 327 (Federal Circuit, 2008)
State v. Hernandez
823 P.2d 1309 (Court of Appeals of Arizona, 1991)
Application of George E. Myers
410 F.2d 420 (Customs and Patent Appeals, 1969)

Cite This Page — Counsel Stack

Bluebook (online)
305 F.2d 501, 49 C.C.P.A. 1196, Counsel Stack Legal Research, https://law.counselstack.com/opinion/application-of-william-true-davis-jr-and-fred-m-murdock-ccpa-1962.